Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

por Kashiwagi, Shinichiro, Yashiro, Masakazu, Takashima, Tsutomu, Aomatsu, Naoki, Ikeda, Katsumi, Ogawa, Yoshinari, Ishikawa, Tetsuro, Hirakawa, Kosei
Publicado 2011

Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study

por Goto, Wataru, Kashiwagi, Shinichiro, Kamei, Yuri, Watanabe, Chika, Aomatsu, Naoki, Ikeda, Katsumi, Ogawa, Yoshinari, Hirakawa, Kosei, Ohira, Masaichi
Publicado 2022

Evaluation of the metastatic status of lymph nodes identified using axillary reverse mapping in breast cancer patients

por Ikeda, Katsumi, Ogawa, Yoshinari, Komatsu, Hisateru, Mori, Yoshihiro, Ishikawa, Akira, Nakajima, Takayoshi, Oohira, Gou, Tokunaga, Shinya, Fukushima, Hiroko, Inoue, Takeshi
Publicado 2012

A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer

por Takashima, Tsutomu, Tokunaga, Shinya, Tei, Seika, Nishimura, Shigehiko, Kawajiri, Hidemi, Kashiwagi, Shinichiro, Yamagata, Shigehito, Noda, Satoru, Nishimori, Takeo, Mizuyama, Yoko, Sunami, Takeshi, Tezuka, Kenji, Ikeda, Katsumi, Ogawa, Yoshinari, Onoda, Naoyoshi, Ishikawa, Tetsuro, Kudoh, Shinzoh, Takada, Minoru, Hirakawa, Kosei
Publicado 2016